The United States Food and Drug Administration (FDA) has granted United States-based Insmed Incorporated (Nasdaq:INSM) breakthrough therapy designation for its brensocatib (formerly known as INS1007) intended for the treatment of adult patients with non-cystic fibrosis bronchiectasis for reducing exacerbations, it was reported on Monday.
The product is a novel oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) presently being developed by the company for the treatment of bronchiectasis and other inflammatory diseases.
Brensocatib has received breakthrough therapy designation based on positive results from the global randomised, double-blind, placebo-controlled Phase two WILLOW study of brensocatib in adults with non-cystic fibrosis bronchiectasis. The company aims to start a phase three program for brensocatib in bronchiectasis in the second half of 2020.
Sionna Therapeutics doses first healthy subject in SION-109 phase one clinical trial
Arcturus Therapeutics granted FDA Orphan Drug Designation for ARCT-032 to treat cystic fibrosis
SpliSense completes SPL84 first-in-human, Phase one clinical trial for cystic fibrosis treatment
Positive Phase 2, Proof-of-Concept Results for VX-548 Published in New England Journal of Medicine
Inogen acquires Physio-Assist, expanding respiratory product portfolio and global presence
cystetic Medicines doses first healthy volunteer in CM001 Phase one clinical trial